Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Targeting tumor suppressor gene pathways is a key strategy in cancer therapy.
• Restoring p53 function has been investigated in numerous clinical trials since 1996 with limited success.
• Abnormalities in the p53 pathway are being exploited for tumor-selective replication of adenoviral vectors.

Purpose of the Study:

• To review the progress and challenges in targeting tumor suppressor genes for cancer therapy.
• To highlight emerging therapeutic strategies involving gene restoration and oncolytic viruses.
• To discuss the potential of novel tumor suppressor genes as future gene therapy targets.

Main Methods:

• Review of clinical trials investigating p53 restoration and oncolytic adenoviruses.
• Analysis of emerging research on other tumor suppressor genes like retinoblastoma (Rb) and PTEN.
• Exploration of microarray technologies for identifying new gene therapy targets.

Main Results:

• Clinical trials targeting p53 have shown limited success to date.
• Oncolytic adenoviruses (e.g., dl1520) demonstrate potential by exploiting p53 pathway defects.
• Identification of new potential gene therapy targets through advanced technologies.

Conclusions:

• Gene therapy targeting tumor suppressor pathways remains a promising but challenging area in oncology.
• Further research into novel targets and therapeutic vectors is crucial for advancing cancer treatment.
• The field is evolving with new technologies identifying multiple candidate genes for future gene therapy applications.